May 25, 2022
COMPASS LTOLE supports dual pathway inhibition for vascular protection
PHRI’s COMPASS Long Term Open Label Extension (LTOLE) “further highlights and supports long-term use of [Factor Xa inhibitor anticoagulant] rivaroxaban,...
Read MoreMay 25, 2022
PHRI’s COMPASS Long Term Open Label Extension (LTOLE) “further highlights and supports long-term use of [Factor Xa inhibitor anticoagulant] rivaroxaban,...
Read MoreMay 11, 2022
PHRI Investigator Aristeidis Katsanos, a member of our stroke and brain health research program, has been given a Young Investigator...
Read MoreMay 9, 2022
Three winners of the PHRI-based transdisciplinary research grant program in Hamilton, Canada (new this year) – called Transforming Tomorrow Today,...
Read MoreMay 3, 2022
PHRI is one of six hubs of research in the new Canadian Heart Function Alliance (CHF Alliance) network launched today...
Read MoreApril 30, 2022
ATLAS S-ICD RCT at PHRI led by Jeff Healey and Blandine Mondesert presented at Heart Rhythm 2022 found that S-ICD reduced lead-related complications for patients compared to TV-ICD.
Read MoreApril 22, 2022
At a recent PHRI townhall, we projected the image of a pair of Dutch wooden clogs as Janette Panhuis began...
Read MoreBack To Top